Being tested: Histone deacetylase (HDAC) inhibitors are potential anticancer agents for the treatment of solid and hematological malignancies., An number of structurally diverse HDAC inhibitors have been identified that inhibit proliferation and induce differentiation and/or apoptosis of tumor cells in animal models. HDAC inhibition causes acetylated nuclear histones to accumulate providing a marker for the biological activity of HDAC HDAC inhibition not only results in acetylation of histones but also transcription factors such as p53 Several of the inhibitors have shown impressive antitumor activity in vivo.
Answered 7/17/2014
3.9k views
5 doctors weighed in across 2 answers
A doctor has provided 1 answer
5 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question